Filtered By:
Condition: Multidrug Resistance

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 957 results found since Jan 2013.

Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells
& H Uludağ
Source: Cancer Gene Therapy - March 1, 2013 Category: Cancer & Oncology Authors: H M AliabadiP MahdipoorH Uludağ Tags: lipophilic polymers Mcl-1 multidrug resistance P-glycoprotein siRNA delivery Source Type: research

Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
In this study, low-density lipoprotein (LDL) was isolated from human plasma and loaded with cholesterol-conjugated siRNA to silence the multidrug resistant gene of tumors. Chol-siRNA/LDL-coupled N-succinyl chitosan nanoparticles loaded with doxorubicin (Dox-siRNA/LDL-SCS-NPs) were then prepared and characterised. The Dox-siRNA/LDL-SCS-NPs had average particle size of 206.4 ± 9.2 nm, entrapment efficiency of 71.06% ± 1.42%, and drug-loading amount of 12.35% ± 0.87%. In vitro antitumor activity revealed that cell growth was significantly inhibited. The accumulation of Dox by fluorescence microscopy and flow cytome...
Source: Biomaterials - April 24, 2014 Category: Materials Science Authors: Zhu QL, Zhou Y, Guan M, Zhou XF, Yang SD, Liu Y, Chen WL, Zhang CG, Yuan ZQ, Liu C, Zhu AJ, Zhang XN Tags: Biomaterials Source Type: research

Binary‐copolymer system base on low‐density lipoprotein‐coupled N‐succinyl chitosan lipoic acid micelles for co‐delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug
Abstract The development of effective and stable carriers of small interfering RNA (siRNA) is important for treating cancer with multidrug resistance (MDR). We developed a new gene and drug co‐delivery system and checked its characteristics. Low‐density lipoprotein (LDL) was coupled with N‐succinyl chitosan (NSC) Lipoic acid (LA) micelles and co‐delivered MDR1 siRNA and paclitaxel (PTX‐siRNA/LDL‐NSC‐LA) to enhance antitumor effects by silencing the MDR gene of tumors (Li et al., Adv Mater 2014;26:8217‐8224). In our study, we developed a new type of containing paclitaxel‐loaded micelles and siRNA‐loaded ...
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - March 23, 2016 Category: Materials Science Authors: Shu‐Di Yang, Wen‐Jing Zhu, Qiao‐Ling Zhu, Wei‐Liang Chen, Zhao‐Xiang Ren, Fang Li, Zhi‐Qiang Yuan, Ji‐Zhao Li, Yang Liu, Xiao‐Feng Zhou, Chun Liu, Xue‐Nong Zhang Tags: Original Research Report Source Type: research

Binary ‐copolymer system base on low‐density lipoprotein‐coupled N‐succinyl chitosan lipoic acid micelles for co‐delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug
Abstract The development of effective and stable carriers of small interfering RNA (siRNA) is important for treating cancer with multidrug resistance (MDR). We developed a new gene and drug co‐delivery system and checked its characteristics. Low‐density lipoprotein (LDL) was coupled with N‐succinyl chitosan (NSC) Lipoic acid (LA) micelles and co‐delivered MDR1 siRNA and paclitaxel (PTX‐siRNA/LDL‐NSC‐LA) to enhance antitumor effects by silencing the MDR gene of tumors (Li et al., Adv Mater 2014;26:8217‐8224). In our study, we developed a new type of containing paclitaxel‐loaded micelles and siRNA‐loaded ...
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - March 23, 2016 Category: Materials Science Authors: Shu ‐Di Yang, Wen‐Jing Zhu, Qiao‐Ling Zhu, Wei‐Liang Chen, Zhao‐Xiang Ren, Fang Li, Zhi‐Qiang Yuan, Ji‐Zhao Li, Yang Liu, Xiao‐Feng Zhou, Chun Liu, Xue‐Nong Zhang Tags: Original Research Report Source Type: research

Abstract LB-13: Hyaluronic acid-based CD44 targeted nanoparticle delivery of combination MDR1 siRNA/paclitaxel to overcome drug resistance in ovarian cancer
A major obstacle in the success of chemotherapy in ovarian cancer is the emergence of multidrug resistance (MDR). Overexpression of the MDR1 gene and corresponding P-glycoprotein (Pgp) efflux pumps is one of the best characterized MDR mechanisms. Although MDR1 siRNA based strategies are emerging as highly promising approaches to reverse MDR, the systemic delivery still remains a great challenge. In the present study, CD44 targeting hyaluronic acid (HA) based self-assembling nanoparticle systems were designed with MDR1 siRNA to evaluate its delivery efficiency and combination anticancer therapeutic efficacy with paclitaxel ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yang, X., lyer, A., hornicek, F., Amiji, M., Duan, Z. Tags: Cancer Chemistry Source Type: research

Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with Ultrasound.
Authors: Bai M, Shen M, Teng Y, Sun Y, Li F, Zhang X, Xu Y, Duan Y, Du L Abstract The overexpression of the breast cancer resistance protein (ABCG2) confers resistance to Adriamycin (ADR) in breast cancer. The silencing of ABCG2 using small interfering RNA (siRNA) could be a promising approach to overcome multidrug resistance (MDR) in cancer cells. To deliver ABCG2-siRNA effectively into breast cancer cells, we used mPEG-PLGA-PLL (PEAL) nanoparticles (NPs) with ultrasound-targeted microbubble destruction (UTMD). PEAL NPs were prepared with an emulsion-solvent evaporation method. The NPs size was about 131.5 ± 6.5 ...
Source: Oncotarget - November 19, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Co ‐delivery of HIF‐1α siRNA and 5‐fluorouracil to overcome drug resistance in gastric cancer SGC‐7901 cells
ConclusionsCo‐delivery of siRNA and 5‐fluorouracil chitosan nanoparticles is an attractive strategy to overcome multidrug resistance.
Source: The Journal of Gene Medicine - September 1, 2017 Category: Genetics & Stem Cells Authors: Yunna Chen, Li Sun, Dongdong Guo, Ziteng Wu, Weidong Chen Tags: RESEARCH ARTICLE Source Type: research

Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer
Conclusions These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
Source: Pharmaceutical Research - December 17, 2014 Category: Drugs & Pharmacology Source Type: research

A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Abstract Lung cancer is a leading cause of cancer-associated mortality worldwide, which has a low survival rate. Multidrug resistance (MDR) is a major obstacle that hinders the treatment of lung cancer. Doxorubicin (DOX) is an anthracycline glycoside antibiotic, having a broad spectrum of anticancer activity against various solid tumors. Juglanin is a natural production, mainly extracted from green walnut husks of Juglans mandshurica, exhibiting various bioactivities. Here, we demonstrated that the combination of drug, gene and nanoparticle overcame MDR, inhibiting lung cancer progression. A novel nanoparticular p...
Source: Biochemical and Biophysical Research communications - October 31, 2017 Category: Biochemistry Authors: Wen ZM, Jie J, Zhang Y, Liu H, Peng LP Tags: Biochem Biophys Res Commun Source Type: research

Efficient nanocarriers of siRNA therapeutics for cancer treatment.
Abstract Nanocarriers as drug delivery systems are promising and becoming popular, especially for cancer treatment. In addition to improving the pharmacokinetics of poorly soluble hydrophobic drugs by solubilizing them in a hydrophobic core, nanocarriers allow cancer-specific combination drug deliveries by inherent passive targeting phenomena and adoption of active targeting strategies. Nanoparticle-drug formulations can enhance the safety, pharmacokinetic profiles, and bioavailability of locally or systemically administered drugs, leading to improved therapeutic efficacy. Gene silencing by RNA interference (RNAi)...
Source: Translational Research : the journal of laboratory and clinical medicine - July 21, 2019 Category: Laboratory Medicine Authors: Subhan MA, Torchilin VP Tags: Transl Res Source Type: research

Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles
Publication date: 1 February 2016 Source:Colloids and Surfaces B: Biointerfaces, Volume 138 Author(s): Yang Wu, Yu Zhang, Wei Zhang, Chunlong Sun, Jianzhong Wu, Jinhai Tang Multidrug resistance (MDR) remains one of major limitation for the successful treatment of many cancers including breast cancer. Co-delivery of chemotherapeutic drugs and small interfering RNA (siRNA) has been developed because of its ability to generate synergistic anticancer effects via different mechanisms of action, to reverse MDR and increase the efficacy of chemotherapeutic drugs in cancer therapy. Herein, we employed a kind of efficient m...
Source: Colloids and Surfaces B: Biointerfaces - December 2, 2015 Category: Biochemistry Source Type: research

Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.
CONCLUSION: Knockdown of NF-κB/p65 with siRNA is an effective strategy for inhibiting HepG2 cell growth by downregulating P-gp expression associated chemosensitization and apoptosis induction. PMID: 26668505 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - December 7, 2015 Category: Gastroenterology Authors: Shi Y, Wang SY, Yao M, Sai WL, Wu W, Yang JL, Cai Y, Zheng WJ, Yao DF Tags: World J Gastroenterol Source Type: research

A polycation coated liposome as efficient siRNA carrier to overcome multidrug resistance
Publication date: 1 November 2017 Source:Colloids and Surfaces B: Biointerfaces, Volume 159 Author(s): Yuqiong Xia, Xiaofei Wang, He Cheng, Mei Fang, Pengbo Ning, Yulu Zhou, Wei Chen, Hongjin Song Multidrug resistance (MDR) is one of the important factors that impede effective chemotherapy against cancer. Codelivery of MDR1 siRNA (silencing ABCB1 gene) and anticancer drug can greatly inhibit tumor proliferation. Here in this work, we synthesized poly(diallyldimethylammonium chloride) (PDADMAC) coated liposome formula as siMDR1 carrier (AL-PDAD-RNA) and applied it to reverse doxorubicin resistance of OVCAR8/ADR cells. The ...
Source: Colloids and Surfaces B: Biointerfaces - August 19, 2017 Category: Biochemistry Source Type: research

Molecules, Vol. 25, Pages 2714: Conjugation of Doxorubicin to siRNA Through Disulfide-based Self-immolative Linkers
Debart Co-delivery systems of siRNA and chemotherapeutic drugs have been developed as an attractive strategy to optimize the efficacy of chemotherapy towards cancer cells with multidrug resistance. In these typical systems, siRNAs are usually associated to drugs within a carrier but without covalent interactions with the risk of a premature release and degradation of the drugs inside the cells. To address this issue, we propose a covalent approach to co-deliver a siRNA-drug conjugate with a redox-responsive self-immolative linker prone to intracellular glutathione-mediated disulfide cleavage. Herein, we report the use...
Source: Molecules - June 10, 2020 Category: Chemistry Authors: Florian Gauthier Jean-R émi Bertrand Jean-Jacques Vasseur Christelle Dupouy Fran çoise Debart Tags: Article Source Type: research

Multifunctional Selenium Nanoparticles: Chiral Selectivity of Delivering MDR-siRNA for Reversal of Multidrug Resistance and Real-time Biofluorescence Imaging
Publication date: Available online 8 May 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Qingchang Chen , Qianqian Yu , Yanan Liu , Dhairya Bhavsar , Licong Yang , Xiaofan Ren , Dongdong Sun , Wenjing Zheng , Jie Liu , Lan-mei Chen In this paper, chiral selenium nanoparticles (L-SeNPs/D-SeNPs) modified with a dinuclear Ruthenium (II) complex were used to effectively deliver siRNA targeting the MDR1 gene. In this co-delivery system, the luminescent dinuclear Ruthenium (II) complex was developed to act as a gene carrier and anti-tumor drug, while offering luminescent imaging to follow the intracel...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 9, 2015 Category: Nanotechnology Source Type: research